Cryo Cell International (CCEL) Q1 2025 earnings summary

Executive summary

• Revenue for the quarter ended February 28, 2025 increased 2% year-over-year to $7.97 million, driven by higher recurring storage fees and growth in product and public banking revenue.

• Net income was $282,855, or $0.03 per share, down from $556,241, or $0.07 per share, in the prior year quarter, reflecting higher interest expense and increased SG&A costs.

• The company paid a $0.25 per share cash dividend, totaling $2.02 million, during the quarter.

• Ongoing arbitration with Duke University over a key license agreement has paused expansion plans and created significant uncertainty.

• Processing and storage fees remained the primary revenue driver, with modest growth in product and public banking revenue.

Financial highlights

• Revenue rose to $7,968,880 from $7,852,235 year-over-year, with a 4% increase in recurring annual storage fees offset by a 12% decline in new domestic specimens processed.

• Net income per diluted share was $0.03, compared to $0.07 in the prior year quarter.

• Cost of sales decreased 4% to $1,984,588, while SG&A expenses increased 5% to $4,638,285.

• Interest expense nearly doubled to $494,962, primarily due to higher debt balances and rates.

• Cash and cash equivalents declined to $223,122 from $560,960 at the prior fiscal year-end.

Outlook and guidance

• The company expects to fund known cash needs for at least the next 12 months through cash, marketable securities, operations, and external capital.

• Further investments in the Duke License Agreement and related expansion are on hold pending arbitration outcome.

• The opening of the Cryo-Cell Institute for Cellular Therapies and the Celle Corp. spinoff are paused.

• Forward-looking statements highlight plans for global expansion, product diversification, and biopharmaceutical manufacturing.

• Transformation into a vertically integrated cellular therapy company is ongoing, supported by a Duke University license agreement.